Chronic graft versus host disease of oral mucosa: review of available therapies.
The use of hematopoetic stem cell transplantation (HSCT) has greatly expanded in the recent years for many neoplastic and hematological disorders. Chronic graft versus host disease (cGVHD) is a major complication of allogeneic HSCT and a major cause of morbidity and mortality. Oral mucosal involvement is frequent in cGVHD and contributes significantly to the overall burden of the condition. Oral medicine professionals should be familiar with various treatment options for oral cGVHD. This review discusses treatment modalities available for the management of oral mucosal manifestations of cGVHD. Available evidence for efficacy and safety of various systemic and topical agents, including corticosteroids, calcineurin antagonists, mycophenolate mofetil, and extracorporeal photopheresis, is reviewed.
Imanguli
Matin M
MM
National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. mimanguli@mail.nih.gov
Pavletic
Steven Z
SZ
Guadagnini
Jean-Pierre
JP
Brahim
Jaime S
JS
Atkinson
Jane C
JC
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009059:Mouth Diseases / Q000188:drug therapy* / Q000209:etiology; D009061:Mouth Mucosa / Q000473:pathology; D017893:Photopheresis
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents